Vir Biotechnology, Inc. (VIR)

From the record

Vir Biotechnology, Inc.'s filings since 2018 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Vir Biotechnology, Inc.'s 9 filed years say what it did: revenue went from $3 million in fiscal 2017 to $69 million in fiscal 2025, up 49.8% a year; it rose in 4 of 8 years; the deepest fall was 96% from fiscal 2022 to fiscal 2025; net income was positive in 2 of 9 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Vir Biotechnology, Inc. lost about 57 cents for every dollar of shareholders' money, and gross profitability: its products earned about 7 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 24 cents per dollar of assets, and net share issuance: its share count grew 1.7% over the year (the filed statements).

From the record

Vir Biotechnology, Inc.'s standing among 102 graded names in its industry family: revenue of $69 million in fiscal 2025 ranks in the top 38% by size; a net margin of -638.9% ranks in the bottom 39%; revenue growth of -65.1% a year over the last 3 filed years ranks in the bottom 3% (its annual reports).

From the record

Vir Biotechnology, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is De, Backer Marianne (President and CEO, as filed), filing under that title since 2023-04-04, 3.6 years (bottom 38% of its family); the 14 officers and directors filing in the last fifteen months have been on the record a median of 2.5 years (bottom 7%); 11 officer or director changes were reported on Form 8-K since 2023-11-13, against the 14 people in charge now (bottom 26%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Vir Biotechnology, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $241 million against no long-term debt tagged leaves 24% of its assets as net cash, bottom 47% of its family; cash from operations less capital spending is -578.5% of revenue (bottom 33%); a gross margin of 100% (top 7%); research spending of 665.1% of revenue (top 31%) (its annual report).

From the record

Vir Biotechnology, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -65.1% a year over the last three filed years against 49.8% over all 9, slowing (bottom 5% of its family); the newest year grew -7.6% (bottom 29%); research spending grew -1.3% a year (bottom 45%); capital spending grew -58.6% a year (bottom 22%) (its annual reports). Vir Biotechnology, Inc. reported 3 product lines in fiscal 2025: License and Collaboration Revenue at $63 million (92%), Other Revenue at $3 million (5%), Grant at $2 million (3%); 2 of 3 grew against the year before (its annual report).

From the record

Vir Biotechnology, Inc.'s newest year against its own record: revenue of $69 million in fiscal 2025 came in 330.7% above the $16 million its prior three years' pace pointed to (top 11% of its family); net income of $438 million against a prior three-year average of $207 million (bottom 12%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 22%) (its annual reports).